Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on 12/08/2025 along with the unaudited financial results for the quarter ended June 30, 2025.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals reported a strong turnaround in Q1 FY26 (quarter ended June 30, 2025) with a profit after tax of ₹338.89 Lakhs, compared to a loss of ₹72.36 Lakhs in the same quarter last year. Revenue from operations rose modestly to ₹3,462.40 Lakhs (vs ₹3,328.63 Lakhs in Q1 FY25), and basic EPS turned positive at ₹1.43 versus a loss of ₹0.31 earlier. Total expenses fell to ₹3,183.07 Lakhs from ₹3,407.02 Lakhs, indicating better cost control. The board also fixed September 19, 2025 as the date for the 30th AGM via video conferencing, with the register of members closed from September 13–19, 2025, and reconstituted the Nomination & Remuneration Committee. The statutory auditor issued an unmodified limited review conclusion but flagged an 'Emphasis of Matter' on overdue foreign currency receivables (₹123 Lakhs), an income tax refund adjustment dispute (₹45.17 Lakhs under writ petition), and prior Minimum Public Shareholding non-compliance for which penalty waiver is being pursued.
The sharp swing from loss to profit is a positive signal for shareholders, showing operational improvement, but the auditor's emphasis-of-matter notes on regulatory non-compliance and pending recoveries are minor red flags to watch. Overall, the results are likely to be viewed favorably in the short term.